Azithromycin as an add-on treatment for persistent uncontrolled asthma in adults: protocol of a systematic review and meta-analysis

Wei Liu,1 Wei Mu,2 Huiting Zhang,3 Jingbo Zhai,4 Xiaodan Li,5 Peng Guan,6 Fu Lian,1 Jihong Feng,1 Shuangjiang Yu,3 Xuepin Wang,3 Jinhua Si,7 Zengtao Sun,8 Yuhong Huang2

ABSTRACT

Introduction Clinical management of asthma remains a public challenge. Despite standard treatment with inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs), asthma remains uncontrolled in a substantial number of chronic asthma patients who risk reduced lung function and severe exacerbations. Azithromycin could have add-on effects for these patients. This study is proposed to systematically evaluate the efficacy of azithromycin as an add-on treatment for adults with persistent uncontrolled symptomatic asthma.

Methods and analysis Two reviewers will perform a comprehensive search of PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and four Chinese electronic databases including China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), WanFang Data and VIP Database from inception to May 2019. Only randomised controlled trials will be included. There is no restriction on language or publication type. Combined oral azithromycin and an ICS or and a LABA will be compared with standard treatment alone or with a placebo. The primary outcomes are the number or frequency of asthma exacerbations, changes in asthma symptoms and lung function. Secondary outcomes include the number or frequency of inhalations of beta-agonists with or without corticosteroids for rescue use, eosinophil counts in blood or sputum, adverse events and others. A meta-analysis will be attempted to provide an estimate of the pooled treatment effect. Otherwise, qualitative descriptions of individual studies will be given.

Ethics and dissemination Ethical approval is not required because no primary data will be collected. Study findings will be presented at scientific conferences or published in a peer-reviewed journal.

PROSPERO registration number CRD42019117272.

INTRODUCTION

Asthma is a major non-communicable chronic disease characterised by variable respiratory symptoms and airflow limitation. It cannot be cured, and currently affects around 334 million people globally. Under-treatment and failure in treatment adherence may lead to disease exacerbations, lifetime disability and even death, creating huge burdens on individuals, families and public health. Studies estimate 10%–20% of patients experience persistent uncontrolled symptoms even on maximised maintenance therapy with inhaled corticosteroids (ICS) or/and long-acting beta-agonists (LABAs). Persistent uncontrolled asthma is characterised by three or more of the following signs: (1) daytime asthma symptoms more than two times per week; (2) night waking due to asthma; (3) reliever needed for symptoms more than two times per week and (4) any activity limitation due to asthma. These patients are at higher risk for asthma exacerbations, lifetime disability and even death. Prevention and control of asthma is high on the WHO’s agenda. The current clinical management of uncontrolled asthma is not satisfactory and warrants additional treatment options.

The aetiology of asthma has not been understood well enough to provide clear guidance for clinical practice. Previous research has recognised three typical airway inflammatory phenotypes, that is, eosinophilic, non-eosinophilic and mixed granulocytic inflammation. Eosinophilic asthma correlates with the Th2/allergic pathways and responds well to steroid therapy. Non-eosinophilic asthma is possibly caused by bacterial or viral...
infections and particulate air pollution, thus being unresponsive to steroid therapy. There is evidence that a portion of asthma is based on non-eosinophilic airway inflammation or mixed granulocytic inflammation, which suggests antibiotics may have a role to play in asthma control.

Macrolides are a class of antibiotics that have been reported clinically effective for all phenotypes of asthma. In addition to their direct antimicrobial activity, evidence indicates that macrolides also have anti-inflammatory and immunomodulatory effects. Azithromycin is a second-generation macrolide antibiotic with anti-inflammatory and immunomodulatory functions and a good pharmacokinetic profile. Findings from clinical and review studies suggest azithromycin as an add-on therapy may bring benefits for patients experiencing persistent uncontrolled asthma.

A 2012 randomised controlled trial (RCT) reports that compared with a placebo, 500 mg of azithromycin three times weekly for 6 months reduced the rate of event-based asthma exacerbations by 0.98 per person and prolonged time to first exacerbation in patients with bronchiectasis. But, it did not improve lung function and health-related quality of life. A 2017 RCT involving 420 persistent asthma patients finds adding 500 mg of azithromycin three times weekly to maintenance therapy for 48 weeks reduced asthma exacerbations by 0.79 per patient-year compared with a placebo and significantly improved asthma-related quality of life.

A 2015 meta-analysis of 17 RCTs involving data from 1306 asthma patients suggests long-term (4 weeks and above) macrolides antibiotics therapy improved forced expiratory volume in one second (FEV₁, weighted mean difference: 0.11, p<0.01), peak expiratory flow (PEF, standard mean difference: 0.25, p<0.001), airway hyperresponsiveness, forced vital capacity (FVC) and FEV₁/FVC, but did not change other lung function indicators, clinical symptoms or quality of life. Seven of the 17 included studies use azithromycin.

As far as we know, no previous systematic review has focused on the effect of azithromycin as an adjuvant to standard treatment for persistent uncontrolled asthma. Individual RCTs came to similar findings for some outcomes and conflicting findings for other outcomes. Moreover, the most relevant meta-analysis has evident heterogeneity as it examines macrolides as a whole, and it fails to include clinically meaningful outcomes such as exacerbation frequency.

With recent publications of high-quality RCTs on this subject, we aim to perform a systematic review and meta-analysis to investigate the effect of azithromycin as an add-on treatment for persistent uncontrolled asthma in adult patients.

METHODS AND ANALYSIS

This protocol is developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols 2015 statement.

Inclusion criteria

Types of study

Studies to be included should meet the following criteria: (1) parallel-group RCTs; (2) evaluate the efficacy and safety of azithromycin as an add-on therapy in addition to standard treatment with ICS or and LABAs for persistent uncontrolled asthma in the adult population. There is no restriction on publication status or language.

Types of participants

The participants are adults with a definite diagnosis of uncontrolled asthma based on at least one of the current or past definitions or guidelines for asthma, such as the Global Initiative for Asthma Guideline.

Interventions and comparisons

The experimental intervention should be oral azithromycin. The control intervention could be a placebo or no treatment. Trials will be excluded if other types of macrolide antibiotics are used. Standard treatment refers to ICS or and LABAs. The treatment duration should be at least 4 weeks.

We will draw the following comparisons:

1. Azithromycin plus standard treatment compared with standard treatment alone.
2. Azithromycin plus standard treatment compared with placebo plus standard treatment.

Types of outcome measures

Primary outcomes

1. Number or frequency of asthma exacerbations. An exacerbation is defined as a deterioration of asthma symptoms requiring short-term systemic corticosteroid treatment, an asthma-related hospitalisation or an emergency room visit.
2. Changes in asthma symptoms. Measurement tools include, but are not limited to, the Asthma Control Test, the 5-item Asthma Control Questionnaire and the Asthma Quality of Life Questionnaire.
3. Lung function indicators, including prebronchodilator FEV₁, FEV₁% of predicted value and PEF and so on.

Secondary outcomes

1. Number or frequency of inhalations of beta-agonists with or without corticosteroids for rescue use.
2. Eosinophil counts in blood or sputum.
3. Changes in fractional exhaled nitric oxide level from baseline.
4. Type and number of adverse events.
5. The number of participant drop-outs.

Search strategy

The review authors responsible for literature searching have been trained in hands-on workshops in this field. We carefully design our search strategy and have a librarian (JS) critically revise the searches to match each database. The searches will be updated before the review is ready for publication.
Electronic searches
Two reviewers (WM and HZ) will perform a comprehensive search of PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and four Chinese databases including China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), WanFang and VIP databases from inception to May 2019 to identify potentially eligible studies. Bridging searches will also be conducted to capture literature published from June 2019 until the final review publication.

An example of our search strategy for PubMed using a combination of MeSH terms and free words is reported in online supplementary appendix 1. There will be no restriction on the language and status of publication.

Searching other resources
We will review the reference lists of identified relevant articles for the possible inclusion of additional studies. Major international clinical trial registries such as ClinicalTrials.gov, the Chinese Clinical Trial Registry and the WHO International Clinical Trials Registry Platform will be searched to identify ongoing or unpublished trials. Google Scholar will be searched to identify grey literature further.

Data collection and analysis

Study selection
Records from electronic database searches will be imported into EndNote to eliminate duplications. Two review authors (WL and WM) will screen citations first by reviewing the title and abstract, and then by reading the full-text according to the prespecified inclusion and exclusion criteria. The decision for including a study will be made independently by each reviewer. Any disagreement will be resolved by discussion or further consultation with a third reviewer (HZ).

Data extraction and management
Two review authors (WL and WM) will independently extract and record the following data from each included study:
1. Publication details: title, authors, publication year, funding and country.
2. Study details: aim, design, inclusion and exclusion criteria, randomisation method, use of allocation concealment, blinding and description of follow-up.
3. Patient characteristics: age, gender, sample size, the number of patients included in the analysis, phenotype of asthma, patient compliance and disease course.
4. Intervention information: duration, dose and dosage, and standard treatment.
5. Outcome: outcome measures reported, tools for outcome assessment and adverse events.

Assessment of risk of bias in included studies
The risks of bias for an individual study will be assessed by two authors (WL and WM) based on the approach recommended by the Cochrane Handbook for Systematic Reviews of Interventions. The following domains will be examined: random sequence generation, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other bias. We will grade each source of bias as high, low or unclear. The ratings and corresponding clarifications will be presented in the ‘Risk of Bias Table’ with a quote from the study report. A study will be considered at low risk of bias if randomisation sequence generation, blinding and outcome data reporting are adequately performed and reported.

Measures of treatment effect
The risk ratio with 95% CI will be used to assess the estimated pooled effect for dichotomous outcomes, and the mean difference with 95% CI will be used for continuous outcomes. Moreover, the standard mean difference with 95% CI will be used to present an intervention effect if the same outcome is measured in various ways.

Assessment of heterogeneity
The χ² test and I² will be used to assess heterogeneity for the study outcomes. An I² value >50% or a p value <0.10 indicates the presence of significant statistical heterogeneity. Subgroup analyses and sensitivity analyses will also be performed to assess potential heterogeneity.

Assessment of reporting biases
If it is possible to include 10 or more studies for one common outcome, we will create a funnel plot to examine publication bias.

Data synthesis
Data will be synthesised to provide estimates of the pooled intervention effect using meta-analysis if these trials evaluate the same intervention for a common outcome with comparable methods. The inverse variance method will be used for continuous data and the Mantel-Haenszel method for dichotomous data. The fixed-effect model will be used for data pooling if statistical heterogeneity is low (p>0.1 or I²<50%). Otherwise, the random-effect model will be adopted to provide a more reasonable estimate of effect. However, if one or two studies dominate the evidence, the random-effect model may grossly overestimate the effect size. In that case, the fixed-effect model will be used to make a more conservative conclusion. The Review Manager V.5.3 software will be used. If sparse data are collected for an outcome which does not allow for quantitative analysis, a narrative summary of the findings from individual studies will be provided instead.

Subgroup analysis and investigation of heterogeneity
We will develop the following subgroup analyses to assess possible clinical heterogeneity (if sufficient data are available) according to:
1. Inflammatory phenotypes (eg, eosinophilic vs noneosinophilic asthma subtype based on serological test results).
2. Treatment durations (e.g., <6 vs 6 months and above).
3. Azithromycin dosage or treatment regimens.
4. Patient age groups (e.g., categorising trials into 18–30, 30–45 and above 45 age groups according to mean age).
5. The comparator intervention (e.g., a blank vs a placebo).

   The $\chi^2$ test will be used in analysing the intervention effect. A $p$ value of <0.05 indicates a statistically significant difference between subgroups.

Sensitivity analysis
We will perform a sensitivity analysis to assess the reliability of the pooled results by excluding trials with a high risk of bias or trials reporting data missing.

Summary of findings table and quality of evidence
The web-based GRADEpro GDT$^{33}$ will be adopted to create a summary of findings table for important outcomes. Quality of the evidence will be evaluated by two reviewers (WL and WM) from five aspects: study limitations, inconsistency, imprecision, indirectness and publication bias. Grading for evidence quality could be high, moderate, low or very low. Any disagreement will be resolved by discussion with a third review author (HZ).

Patient and public involvement
We did not seek patient or public involvement in the draft of the protocol. Nor will we enlist patient and public opinion or help in the conduct of this systematic review and meta-analysis.

Amendments
The date, the rationale and a description of the changes made will be provided in the event of protocol amendments.

ETHICS AND DISSEMINATION
Ethical approval is not required because no primary data are collected. This review will provide a comprehensive assessment of the efficacy of azithromycin as an add-on treatment for persistent uncontrolled asthma in adults. Findings of this study could be used as a reference for the clinical management of the target population. Findings of this meta-analysis will be presented at scientific conferences and be published in scientific journals.

Protocol registration and progress
This review protocol is registered with PROSPERO. As of October 2019, the reviewers have completed the literature search and are screening trials.

Author affiliations
1Department of Respiratory Medicine, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
2Department of Clinical Pharmacology, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
3Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China
4Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China

REFERENCES
1 Papi A, Brightling C, Pedersen SE, et al. Asthma. The Lancet 2018;391:783–800.
2 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. The Lancet 2012;380:2163–96.
3 World Health Organization, Asthma. Available: http://www.who.int/en/news-room/fact-sheets/detail/asthma [Accessed 10 May 2019].
4 Bateman ED, Boushey HA, Bouquet J, et al. Can guideline-defined asthma control be achieved? the gaining optimal asthma control study. Am J Respir Crit Care Med 2004;169:836–44.
5 Hermosa JLR, Sánchez CB, Rubio MC, et al. Factors associated with the control of severe asthma. J Asthma 2010;47:124–30.
6 Peters SP, Ferguson G, Deniz Y, et al. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139–51.
7 The Global Initiative for Asthma Group. Pocket Guide for Asthma Management and Prevention. 2018. 9. Available: https://ginasthma.org/wp-content/uploads/2018/03/wms-GINA-main-pocket-guide_2018-v1.0.pdf
8 Calhoun WJ, Haselkorn T, Mink DR, et al. Clinical burden and predictors of asthma exacerbations in patients on Guideline-based steps 4-6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol 2012;129:193–200.
9 Ivanova JL, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012;129:1229–35.
10 Gibson PG, Yang IA, Uphaam JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. The Lancet 2017;389:659–68.
11 Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322–9.
12 Douwes JE, et al. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002;57:643–8.
13 Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. *J Allergy Clin Immunol* 2007;119:1043–52.

14 Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics – Part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. *Respiration* 2011;81:75–87.

15 Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am J Respir Crit Care Med* 2007;175:1043–52.

16 Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics – Part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. *Respiration* 2011;81:75–87.

17 Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. *J Allergy Clin Immunol* 2007;119:1043–52.

18 Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics – Part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. *Respiration* 2011;81:75–87.

19 Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am J Respir Crit Care Med* 2007;175:1043–52.

20 Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics – Part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. *Respiration* 2011;81:75–87.

21 Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. *J Allergy Clin Immunol* 2007;119:1043–52.